VCU technology could upend DNA sequencing for diagnosing certain DNA mutations

January 27, 2021

Doctors are increasingly using genetic signatures to diagnose diseases and determine the best course of care, but using DNA sequencing and other techniques to detect genomic rearrangements remains costly or limited in capabilities. However, an innovative breakthrough developed by researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Department of Physics promises to diagnose DNA rearrangement mutations at a fraction of the cost with improved accuracy.

Led by VCU physicist Jason Reed, Ph.D., the team developed a technique that combines a process called digital polymerase chain reaction (dPCR) with high-speed atomic force microscopy (HSAFM) to create an image with such nanoscale resolution that users can measure differences in the lengths of genes in a DNA sequence. These variations in gene length, known as polymorphisms, can be key to accurately diagnosing many forms of cancer and neurological diseases.

A study detailing the method was recently published in the journal ACS Nano, and the research team reported their results at the annual meetings for the Association of Molecular Pathology and the American Society of Hematology. Previous research detailing the HSAFM technology was described by VCU Massey Cancer Center in 2017.

"The technology needed to detect DNA sequence rearrangements is expensive and limited in availability, yet medicine increasingly relies on the information it provides to accurately diagnose and treat cancers and many other diseases," says Jason Reed, Ph.D., member of the Cancer Biology research program at VCU Massey Cancer Center and associate professor in the Department of Physics at the VCU College of Humanities and Sciences. "We've developed a system that combines a routine laboratory process with an inexpensive yet powerful atomic microscope that provides many benefits over standard DNA sequencing for this application, at a fraction of the cost."

dPCR uses the DNA polymerase enzyme to exponentially clone samples of DNA or RNA for further experimentation or analysis. The sample is then placed on an atomically flat plate for inspection using HSAFM, which drags an extremely sharp microscopic stylus similar to the needle on a record player across the sample to create precise measurements at a molecular level. The technique was adapted by Reed's team to use optical lasers, like those in a DVD player, to process samples at a rate thousands of times faster than typical atomic force microscopy. The researchers then developed computer code to trace the length of each DNA molecule.

The team claims that each dPCR reaction costs less than $1 to scan using their technique.

To demonstrate the clinical utility of the process, Reed partnered with Amir Toor, M.D., hematologist-oncologist and member of the Developmental Therapeutics research program at Massey, and Alden Chesney, M.D., associate professor of pathology in the Department of Pathology at the VCU School of Medicine. Together, they compared Reed's technique to the current standard test to diagnose DNA length polymorphisms in the FLT3 gene in patients with acute myeloid leukemia. Patients with these mutations typically have a more aggressive disease and poor prognosis when compared to patients without the mutation.

Reed's technique accurately identified FLT3 gene mutations in all samples and matched the results of the current gold standard test (LeukoStrat® CDx FLT3 Mutation Assay) in measuring the lengths of the gene segments. However, unlike the current test, Reed's analysis also reports the variant allele fraction (VAF). The VAF can show whether the mutation is inherited and allows the detection of mutations that could potentially be missed by the current test.

"We chose to focus on FLT3 mutations because they are difficult to diagnosis, and the standard assay is limited in capability," says Reed. "We plan to continue developing and testing this technology in other diseases involving DNA structural mutations. We hope it can be a powerful and cost-effective tool for doctors around the world treating cancer and other devastating diseases driven by DNA mutations."
-end-
In addition to Toor and Chesney, Reed collaborated on his research with Sean Koebley, Ph.D., Andrey Mikheikin, Ph.D., Kevin Leslie, Ph.D., Daniel Guest, Wendy McConnell-Wells, Joshua Lehman, and Loren Picco, Ph.D., all from the VCU Department of Physics; and Taha Al Juhaishi, M.D., Xiaojie Zhang, M.D., and Catherine Roberts, Ph.D., all from the Cellular Immunotherapies and Transplant Program at VCU Massey Cancer Center and the Department of Internal Medicine at VCU School of Medicine.

Funding for the research was provided by National Institutes of Health grants R01GM094388 and NIH K12GM093857, grants from Virginia's Commonwealth Health Research Board (236-08-19) and, in part, by VCU Massey Cancer Center's NCI Cancer Center Support Grant P30 CA016059.

Virginia Commonwealth University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.